Routine Doses of Enrofloxacin Achieve Pharmacodynamic Target Likely to Treat Susceptible and Susceptible Dose‐Dependent Bacterial Infections in Critically Ill Dogs
Journal of Veterinary Pharmacology and Therapeutics · 2025
DOI: 10.1111/jvp.13519 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Pharmacology and Therapeutics, 2025. Verfasst von Robert Goggs und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA. Hauptthemen laut MEDLINE: Enrofloxacin, Anti-Bacterial Agents, Dog Diseases, Bacterial Infections. Die Arbeit nennt 95 Literaturangaben. Gefördert von: Cornell University.
Abstract (Originalsprache)
The fluoroquinolones, particularly enrofloxacin, are frequently used to treat life‐threatening bacterial infections in small animal emergency and critical care practice. Achieving therapeutic plasma concentrations is essential for effective treatment, whereas inadequate concentrations select for resistance among Enterobacterales and Pseudomonas aeruginosa . We conducted a prospective observational study in 19 critically ill dogs to evaluate the pharmacokinetics (PK) of enrofloxacin and its active metabolite ciprofloxacin after administration of a standardized dosage (10 mg/kg IV q24 h). Plasma concentrations were measured at multiple time points using liquid chromatography‐mass spectrometry, and PK modeling was performed to determine best‐fit compartmental models. A 2‐compartment model best described enrofloxacin PK. There was considerable between‐dog variation in PK parameters, likely due to known challenges of drug dosing in critical illness. The percentage conversion of enrofloxacin to ciprofloxacin was lower than has previously been reported in healthy dogs. Pharmacodynamic analyses suggest that enrofloxacin administered at 10 mg/kg IV q24 h to critically ill dogs will likely result in effective treatment of infections by susceptible and susceptible dose‐dependent bacteria, and achieved concentrations may be sufficient to reduce the risk of AMR development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA.
- Comparative Coagulation Laboratory, Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA.
- Department of Veterinary Diagnostic and Clinical Sciences, Faculty of Veterinary Medicine, University of Calgary, Calgary, Alberta, Canada.
- Department of Molecular Biomedical Sciences, NC State University, Raleigh, North Carolina, USA.
ORCID-Profile: Robert Goggs, Julie Menard, Jeff Beverly
Förderung
- Cornell University
Zitieren
APA
Goggs, R., Robbins, S., Menard, J., Selman, J., Beverly, J., Kraus-Mallet, S., & Papich, M. G. (2025). Routine Doses of Enrofloxacin Achieve Pharmacodynamic Target Likely to Treat Susceptible and Susceptible Dose‐Dependent Bacterial Infections in Critically Ill Dogs. Journal of Veterinary Pharmacology and Therapeutics. https://doi.org/10.1111/jvp.13519
Vancouver
Goggs R, Robbins S, Menard J, Selman J, Beverly J, Kraus-Mallet S, et al. Routine Doses of Enrofloxacin Achieve Pharmacodynamic Target Likely to Treat Susceptible and Susceptible Dose‐Dependent Bacterial Infections in Critically Ill Dogs. Journal of Veterinary Pharmacology and Therapeutics. 2025. doi:10.1111/jvp.13519
BibTeX
@article{Goggs2025,
author = {Goggs, Robert and Robbins, Sarah and Menard, Julie and Selman, Jamie and Beverly, Jeff and Kraus-Mallet, Sydney and Papich, Mark G},
title = {Routine Doses of Enrofloxacin Achieve Pharmacodynamic Target Likely to Treat Susceptible and Susceptible Dose‐Dependent Bacterial Infections in Critically Ill Dogs},
journal = {Journal of Veterinary Pharmacology and Therapeutics},
year = {2025},
doi = {10.1111/jvp.13519}
}
EUVIMED